AlphAIAlphAI — Financial news for AI agents
investing.com$OABI

Stifel reiterates OmniAb stock rating on technology platform

Stifel maintained a Buy rating and $9.00 price target for OmniAb (OABI), citing its technology platform and upcoming catalysts. The stock has fallen 12.3% in a week but risen 188% in six months. OmniAb reported Q2 2026 earnings beating estimates, with revenue of $13.41M vs. $4.95M expected.

Original reporting
investing.com
Published Oct 7, 2026, 12:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$OABI
Bullish
medium confidence
Mentioned
$OABI
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OABIBullishLow
01

Why it matters

Analyst upgrade with a higher target may attract buying interest.

02

Market read

Analyst reiteration with a higher price target provides modest new insight but no material corporate event.

03

Timing

none

Relevance 4/10Novelty 2/10Timing: none

Background

OmniAb is a biotech focused on peptide discovery platforms. The article repeats Q2 2026 results that were released over two months earlier.

Company-level read

Ticker impact

$OABIBullishMedium confidence
Context

Stifel reiterated a Buy rating and raised the price target to $9.00 after OmniAb's investor event, providing fresh analyst coverage.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

The new $9 target is more than double the current price, suggesting upside potential despite recent pullback.

Read at source← All news

Related articles

$OABIMed

OmniAb Inc (OABI) (Q3 2026) Earnings Call Highlights: Lilly Deal, Raised Guidance

OmniAb Inc (OABI) reported Q3 2026 earnings, highlighting raised guidance and a busy pipeline. Milestones remain the largest revenue contributor, with royalties expected to grow from IMVT-1402 in late 2028. Exploration revenue is projected to double in 2027 and 2028. The company expects $340M in potential milestones from active clinical programs. OmniTides, a new peptide workflow, is attracting partner interest. Bataclimab's royalty contribution in China is uncertain pending launch details.

finance.yahoo.com
$OABIMed

OmniAb (OABI) Q3 2026 Earnings Call Transcript

OmniAb (OABI) reported Q3 2026 earnings, highlighting a new partnership with Lilly, which includes an upfront payment and up to $370M in potential milestone payments. The company saw increased utilization of its technologies and strong traction with its xPloration platform. OmniAb also launched OmniTides, a new peptide discovery offering. The company raised its 2026 revenue and cash outlook, and reported 111 active partners and 433 active programs as of Q3.

finance.yahoo.com
$OABIMedAI 8/10

OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook

OmniAb Inc. (OABI) shares rose about 18% in premarket after the company increased its 2026 cash forecast. OmniAb now expects $49 million to $53 million in cash and cash equivalents, up from $37 million to $41 million, citing recent license and business-development agreements, including a technology contract with Eli Lilly for its ion-channel program.

yahoo.com